Start A Thread

Rate Bioventus

  • Culture

  • Compensation

  • Opportunity for advancement

  • Realistic plan attainment

×

Salaries

In our drive to help people in the medical sales industry we are gathering salary data. This information will be collated, analyzed and number crunched. Medtechy’s overall goal is to help the medical sales industry make more informed decisions when changing jobs and also keep employers and recruiters honest

Take 30 seconds and let us know your current deal.*

About The Position

Compensation

* We guarantee all data collected is completely anonymous and will only be used for the benefit of future visitors.

×

Hot Ticker Articles

Abbott CEO gives a great lesson in accountability

Abbott's Medical Device Business is Rolling

JNJ Medical Device Business Continues to Lag

Diabetes is a main ingredient in Medtronic's Value Based Healthcare Program

JNJ beats earnings on pharma sales, cuts full year forecast

Nevro fires sales VP. Stock down over 17%

Bioventus Message Board


Does Exogen work? Nope

4 months ago

It hasn't affected my sales at all. Most customers don't even care about these studies.

RIP Exogen, Part Deux

9 months ago

Coverage reductions and management decisions are bringing this glorious product to a slow death.

Goodbye my special friend. Good bye.

Bioventus News

10 months ago

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN

Durham, NC- September 13, 2017 - Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three observational, non-interventional, direct-to-patient studies designed to collect real world data on the use of the EXOGEN Ultrasound Bone Healing System. EXOGEN uses safe, e…

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN® Durham, NC– September 13, 2017 – Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three observational, non-interventional, direct-to-patient studies designed to collect real world data on the use of

Bioventus Delays IPO

2 years ago

Bioventus Delays IPO

Bioventus, a global leader in orthobiologics, postponed their IPO on Friday.The Durham, NC based company filed for their initial public offering in early July hoping to raise $150 million by offering 8.8 million shares at a price range of $16 to $18.

ES Reps, 2015 and Beyond

4 years ago

Yes. Everyone is going to go work for DJ Ortho and BV will crumble.

Bioventus is Now a Stepping Stone

4 years ago

I feel like we're always hiring due to so many departures. I noticed a bunch of positions posted online for reps.

Loading...